Old World monkey TRIM5a targets incoming human immunodeficiency virus type 1 (HIV-1) viral capsid, whereas the apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like (APOBEC)3 family hypermutate/degrade viral sequences. Here, we show the potentials of simian TRIM5a and APOBEC3G as therapeutic sequences for AIDS gene therapy. Both rhesus and African green monkey (agm) TRIM5a efficiently restrict HIV-1 vectors with divergent Gag from different HIV-1 subtypes. Human T cells genetically engineered to express agm-TRIM5a block or delay HIV-1 replication. Although agm-APOBEC3G expression alone only transiently suppresses HIV-1 replication, co-expression of agm-APOBEC3G and agm-TRIM5a successfully block the virus replication for more than 5 weeks.
Introduction
The gene therapy approach for AIDS using therapeutic sequences that block viral replication has been extensively studied. So far, intracellular antibodies against viral proteins, 1 anti-human immunodeficiency virus Type 1 (HIV-1) ribozymes, [2] [3] [4] [5] RNA decoys, 6 transdominant viral genes, 7, 8 antisense and short interfering RNA (siRNA) against viral and essential cellular proteins for HIV-1 replication [9] [10] [11] [12] [13] [14] have been used as therapeutic constructs. However, the inhibitory effects on HIV-1 replication by anti-HIV-1 ribozymes, decoys or antisense constructs are generally mild. Although sequence-specific degradation of viral mRNA by siRNA constructs strongly inhibit HIV-1 replication, the emergence of escape mutants with few mutations in the siRNA target region can avoid the anti-viral activity of siRNA. 15 Recently, two intrinsic cellular factors, which control HIV-1 permissivity in primate cells, were identified as TRIM5a and apolipoprotein B mRNA-editing enzymecatalytic polypeptide-like (APOBEC)3 proteins. [16] [17] [18] TRIM5a targets incoming HIV-1 viral capsid (CA), 17, [19] [20] [21] whereas the APOBEC family hypermutates/degrade viral sequences. 22, 23 As simian TRIM5a and APOBEC3 proteins have been shown to restrict broad ranges of retro/lentiviruses, we hypothesized that such intrinsic anti-viral factors might serve as ideal therapeutic sequences for HIV-1 gene therapy, which could block genetically divergent HIV-1 isolates. In this study, we examined the potentials of simian restriction factors as therapeutic sequences for AIDS gene therapy.
Rhesus and African green monkeyTRIM5a can block HIV-1 vectors with widely divergent Gag sequences
For AIDS gene therapy, it would be ideal if the therapeutic sequences could restrict divergent HIV-1 isolates. First, we asked if simian TRIM5a could block HIV-1 vectors with divergent, naturally occurring Gag substitutions in human cells. Retroviral vector plasmids, pDon-rT5 and pDon-aT5, were made by introducing rhesus (rh)-and African green monkey (agm)-TRIM5a cDNA into pDon-AI (Takara Mirus Bio, Shiga, Japan). We established TRIM5a-expressing TE671 cells (ATCC CCL-136) by retroviral transduction and subsequent selection in the presence of G418 (1 mg/ml). The green fluorescent protein (GFP)-expressing, vesicular stomatitis virus (VSV)-G-pseudotyped viral vectors with Gag sequences from different HIV-1 subtypes were prepared as reported previously 24 ( Figure 1a) . We infected the cells with or without rh-TRIM5a expression with the GFP-carrying vectors. GFP-positive cells were analyzed by flow cytometry 3 days after infection. As shown in Figure  1b , rh-TRIM5a-expressing TE671 cells were 20-to 50-folds more resistant than control TE671 cells to infection by all the HIV-1 vectors tested. The agm-TRIM5a-expressing TE671 cells showed essentially identical results as TE671 with rh-TRIM5a (data not shown), suggesting that both rh-and agm-TRIM5a can efficiently block HIV-1 with divergent Gag sequences.
Rh-and agm-TRIM5a restricts HIV-1 replication in vitro Next, we asked if the simian TRIM5a-expressing cells can block replication-competent HIV-1. The titers of dualtropic HIV-1, 89.6, 25 and T-tropic HIV-1, NL4-3, 26 were determined in GHOST(3)R3/X4/R5 indicator cells.
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Simian TRIM5a-expressing CEMx174 and MT-4 cells were established by retroviral transduction. The G418-resistant bulk populations of control, rh-TRIM5a-positive and agm-TRIM5a-positive MT-4 or CEMx174 cells were designated as MT-ct, MT-rT5 and MT-aT5, or CEM-ct, CEM-rT5 and CEM-aT5, respectively. We did not use clonal populations, because bulk populations represent more realistic models for actual gene therapy setting. We confirmed the TRIM5a expression by resistance to HIV vector infection; the TRIM5a-expressing MT-4 and CEMx174 cells were 12-and 5-fold more resistant to HIV vector infection than their parental control cells, respectively ( Figure 2a) . The MT-ct, MT-rT5 and MT-aT5 cells (3.0 Â 10 4 ) were infected with NL4-3 or 89.6 at doses equivalent to multiplicities of infection (MOI) of 0.02 on GHOST R3/ X4/R5 cells, referred to as GHOST MOI. Two hours after infection, the cells were washed once and then plated in six-well plates. The culture supernatants were harvested at various time points and subjected to Retrotek p24 antigen enzyme-linked immunosorbent assay (ELISA; Zeptomatrix Corporation). Cell viability was assessed by Trypan blue staining to quantify dead cells.
The NL4-3-and 89.6-infected MT-ct cells showed numerous large syncytia as early as 5 days post infection (p.i.) and most of the cells were killed by 10 days p.i. No cells survived more than 20 days (Figure 2b ). In sharp contrast, p24 was under the detectable level (o25 pg/ ml) in the 89.6-infected MT-aT5 supernatants for 7 weeks (Figure 2b , data not shown after 6 weeks p.i.), indicating that the agm-TRIM5a successfully restricted the 89.6 replication in MT-4 cells. In the NL4-3-infected MT-rT5 and MT-aT5 or the 89.6-infected MT-rT5, no cytopathic effects were observed until 7 days p.i. However, the block was transient. The cultures started to show a few small syncytia at 10 days p.i., which aggressively fused with neighboring cells and formed numerous large syncytia by 12 days p.i. The p24 assay using the culture supernatants demonstrated the delayed viral replication kinetics in the TRIM5a-expressing cells (Figure 2b ). These observations suggest that the simian TRIM5a can block or reduce the initial cell-free HIV-1 infection, but not strongly prevent cell-associated viruses from spreading in the culture. Interestingly, small populations of the cells survived in the NL4-3-infected MT-rT5 and MT-aT5 or the 89.6-infected MT-rT5 cultures (Figure 2b ). It is likely that the cells, which expressed high levels of simian TRIM5a, became predominant in the cultures. However, the surviving cells in the NL4-3-infected cultures were eventually killed following the formation of numerous large syncytia by 7 weeks p.i. In order to Intrinsic restriction factors for AIDS gene therapy R Sakuma et al assess the possibility that escape mutants with certain mutations in their CA sequences emerged in the culture, we amplified and cloned the CA region of the recovered viruses, but found no significant changes. In accordance with this result, the cell-free viruses recovered from the infected MT-rT5 and MT-aT5 cells at 7 weeks p.i. could replicate efficiently in uninfected MT-ct but not in MTaT5 cells (data not shown), suggesting that the recovered viruses were still restricted by agm-TRIM5a-mediated restriction. These observations indicate that simian TRIM5a cannot strongly block HIV-1 replication through cell-cell fusion. Indeed, co-culturing NL4-3-infected MT-4 cells (5000 cells) with uninfected MT-aT5 or MTrT5 cells (500 000 cells) resulted in rapid formation of numerous large syncytia in the cultures (data not shown). In CEMx174-derived cells, agm-TRIM5a was able to block 89.6 replication and delayed the growth kinetics of NL4-3. In contrast, CEM-rT5 cells did not delay NL4-3 or 89.6 growth kinetics, although the infected CEM-rT5 cells were more protected from the cytopathic effects than the CEM-ct (Figure 2b ).
Co-expression of agm-APOBEC3G and agm-TRIM5a efficiently block HIV-1 replication
Although human APOBEC3G has potent antiretroviral activity against HIV-1, this restriction is counteracted by the HIV-1 virion infectivity factor (Vif) protein. In contrast, HIV-1 Vif cannot neutralize agm-APOBEC3G. 34 We therefore examined the anti-viral effects of agm-APOBEC3G on HIV-1 replication. The HA-tagged agm-APOBEC3G-expressing retroviral vector, pBabe-puroaA3G, was produced by cloning the EcoRI-XhoI fragment of pc-AGM-APOBEC3G-HA into the EcoRI-SalI sites of pBabe-puro. In order to examine the impacts of simian APOBEC3G expression on HIV-1 replication, we introduced agm-APOBEC3G into MT-ct and MT-aT5 cells by retroviral vector transduction. The transduced cells were then selected under the presence of 2 mg/ml puromycin. The agm-APOBEC3G expression in the puromycinresistant bulk populations was confirmed by immunoblotting using mouse-anti-HA monoclonal antibody, HA.11 (COVANCE) (Figure 3a) . The agm-APOBEC3G-expressing MT-ct and MT-aT5 were designated as MT-A3 and MT-aT5-A3, respectively. We then infected MT-ct, MT-A3, MT-aT5 and MT-aT5-A3 cells with NL4-3 or 89.6 at GHOST MOI of 0.01. When compared with the infected MT-ct cells, the p24 production in the NL4-3-and 89.6-infected MT-A3 showed delayed viral replication kinetics. As seen previously (Figure 2b ), NL4-3 replication was delayed, whereas 89.6 was successfully restricted in the infected MT-aT5 cells. Intriguingly, coexpression of agm-TRIM5a and agm-APOBEC3G potentiated the anti-viral effects of agm-TRIM5a. p24 was undetectable until 5 weeks p.i. in the NL4-3-infected MTaT5-A3, although 77 ng/ml of p24 was detected in the culture at 6 weeks p.i. (Figure 3b) . No p24 was detected in the 89.6-infected MT-aT5-A3 cells for up to 6 weeks p.i. We also challenged the MT-4-derived cells with 100-fold higher doses of NL4-3 (GHOST MOI of 1). Although the MT-aT5-A3 cells failed to completely block NL4-3 replication, the cells impaired the viral replication and the cells were more protected from the cytopathic effects than the infected MT-ct, MT-A3 or MT-aT5 (Figure 3b) . Similarly, co-expression of agm-APOBEC3G and agmTRIM5a in CEMx174 cells successfully restricted 89.6 replication (MOI 0.01), and delayed NL4-3 replication more efficiently than agm-TRIM5a alone (data not shown).
In this study, we demonstrated the potentials of simian TRIM5a and APOBEC3G as therapeutic sequences for AIDS gene therapy. Infectivity of HIV-1 vectors with divergent Gag sequences were reduced 20-to 50-fold by simian TRIM5a (Figure 1 ), suggesting that simian TRIM5a can block highly divergent strains of HIV-1 in human cells. This is a favorable feature as a therapeutic sequence for HIV-1 gene therapy, because it may not allow HIV-1 to easily escape from the restriction. One of the hallmarks of TRIM5a-mediated resistance to lentiviral infection is that the block is most evident at a low MOI and that infection by an otherwise restricted virus is strongly facilitated by the presence of other restricted virion particles. 28, 29 We showed that the agm-TRIM5a alone could successfully block the replication of 89.6 but not NL4-3. As laboratory-adapted NL4-3 replicates more aggressively than dual-tropic 89.6 in vitro (Figures 2b and  3b) , it is likely that NL4-3 could overcome the restriction by producing enough high titers that saturated the restriction. However, it should be difficult for the virus Intrinsic restriction factors for AIDS gene therapy R Sakuma et al to overcome the restriction in vivo where the adaptive immune system keeps viral titers low. Thus, the nonpermissive TRIM5a-expressing cells may have good advantages to repopulate in patients at early stages of HIV-1 infection.
Intriguingly, the agm-TRIM5a-expressing cells were generally more resistant to HIV-1 replication than the rh-TRIM5a-expressing cells (Figure 2b ). This observation was reproducible both in MT-4 and CEMx174. It is notable that the agm-TRIM5a has broader specificity for viral CAs than does rh-TRIM5a. Agm-TRIM5a is able to restrict MLV-N, HIV-1, SIVmac and EIAV compared with rh-TRIM5a strongly restricting only HIV-1. [19] [20] [21] Thus, it is plausible that agm-TRIM5a has higher affinity to HIV-1 CA than rh-TRIM5a to block HIV-1 infection. Alternatively, agm-TRIM5a may block two distinct steps of HIV-1 infection, that is, early after viral entry before reverse transcription, as seen in rh-TRIM5a restriction, as well as after reverse transcription, which was reported in squirrel monkey TRIM5a. 30 Incorporation of the APOBEC family of cytidine deaminases into HIV-1 particles results in the hypermutation/degradation of viral cDNA. 22, 23 Recently, Chiu et al. 31 reported that human APOBEC3G functions as a potent post-entry restriction factor for HIV-1 in unstimulated CD4+ T cells. Although agm-APOBEC3G alone could transiently delay HIV-1 replication when infected at MOI of 0.01, we did not see any block when the cells were infected at MOI of 1 (Figure 3b) . Thus, it is suggested that agm-APOBEC3G did not efficiently block incoming HIV-1 in the MT-A3 cells but worked predominantly through incorporation into HIV-1 particles. Intriguingly, co-expression of agm-APOBEC3G significantly enhanced the anti-viral effects of agm-TRIM5a and successfully blocked the virus replication for more than 5 weeks (Figure 3b ). This is possibly because the APOBEC3G could prevent HIV-1 from producing enough high titers of progeny viruses to overcome the TRIM5a-mediated restriction.
In the course of our study, efficient restriction of HIV-1 replication by rh-TRIM5a in the CD34 + -derived macrophages was reported. 32 Specifically, the authors have successfully shown that rh-TRIM5a expression can delay and reduce p24 production in the HIV-1 Ba-L-and NL4-3-infected cells. Here, we demonstrated a promising potential of co-expression of simian TRIM5a and APOBEC3G as therapeutic sequences for HIV-1 gene therapy. Recent studies demonstrated that single aminoacid substitutions in the human TRIM5a and human APOBEC3G could render the human proteins potent restriction factors against HIV-1. [33] [34] [35] [36] [37] Thus, as suggested by Yap et al., 37 we can use the R332P derivative of human TRIM5a, in combination with the Vif-insensitive, K128D derivative of human APOBEC3G, as ideal alternatives to reduce host immune response to the restriction factors.
